Antibody Drug Conjugates Market Growth Accelerates at 11.04% CAGR, Valued at USD 34.87 Billion by 2034

Antibody Drug Conjugates Market Overview:

Antibody drug conjugates (ADCs) are a class of targeted cancer therapies designed to combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The antibody component selectively binds to antigens on cancer cell surfaces, delivering the attached drug directly to tumor cells while minimizing damage to healthy tissues.

According to the global antibody drug conjugates market size is valued at USD 13.63 billion in 2025 and is anticipated to grow from USD 15.41 billion in 2026 to USD 34.87 billion by 2034, growing at a CAGR of 11.04% from 2026 to 2034. The market growth is primarily attributed to the growing regulatory approvals of novel ADCs, a surge in merger and acquisition activities, and a rise in the incidence of new cancer cases across the globe.

Download the Sample Pages of this Report for Better Understanding @ https://straitsresearch.com/report/antibody-drug-conjugates-market/request-sample

Market Dynamics

The increasing incidence of cancer drives the demand for ADCs

The increasing prevalence of various cancers is a major factor driving the demand for ADCs for targeted disease management. In the U.S. and other countries, healthcare professionals offer ADCs over chemotherapy to treat cancers effectively.

For instance, the American Cancer Society (ACS) projected that 2,041,910 new cancer cases would be diagnosed in the U.S.

This trend is expected to boost demand for ADCs over chemotherapy, thereby driving the market growth.

Technological advancements and next-generation ADCs

The advancement of ADCs is a promising opportunity for future market growth. The development of multi-payload and the emergence of site-specific linkers are transforming the treatment landscape. These novel ADCs are designed to more effectively target tumors while minimizing side effects, which will lead to increased demand for ADCs.

For instance, companies such as MediLink and Celltrion Pharma have preclinical dual payload ADCs that deliver two different drugs targeting tumors that resist a single agent. This development combines a topoisomerase I inhibitor with MMAE, which effectively kills the cancer cells.

Therefore, such innovations are expected to boost research and adoption of ADCs globally.

Antibody Drug Conjugates Market Segmentation

By Product Type
Adcetris
Kadcyla
Enhertu
Padcev
Trodelvy
Others

By Application
Blood Cancer
Breast Cancer
Urothelial Cancer
Lung Cancer
Others

By Target
CD33
HER2
CD30
TROP2
Others

By Region
North America
Europe
Asia-Pacific
Latin America
The Middle East and Africa

Get Detailed Market Segmentation @ https://straitsresearch.com/report/antibody-drug-conjugates-market/segmentation

Competitive Players

Hoffmann-La Roche Ltd.
Daiichi Sankyo
Pfizer Inc.
Gilead Sciences
AstraZeneca
AbbVie Inc.
ADC Therapeutics
Genmab A/S
Astellas Pharma Inc.
RemeGen Co., Ltd.
GSK plc
Takeda Pharmaceuticals
Hansoh Pharmaceutical Group Company Limited.
Eli Lilly and Company
Bristol-Myers Squibb Company

To Visit Here For Grab More Insights @ https://straitsresearch.com/report/antibody-drug-conjugates-market

Key Highlights

By product type, the market is segmented into Adcetris, Kadcyla, Enhertu, Padcev, Trodelvy, and others. The Kadcylasegment dominates the market with a revenue share of 28.86% in 2025. This growth is attributed to the highest revenue generation from U.S. and international sales due to its high potency to treat cancers as compared to other ADCs.

By application, the market is categorized into blood cancer, breast cancer, lung cancer, and others. The breast cancer segment is estimated to grow at the fastest pace with a CAGR of 12.4%, owing to its high prevalence and increasing new ADC approvals targeting the breast cancer indication.

On the basis of the target, the market is divided into CD33, HER2, CD30, TROP2, and others. The HER2 segment dominated the market in 2025 and is estimated to grow with the fastest CAGR, owing to high target specificity and availability of HER2-targeted ADCs in the market.

Asia Pacific is estimated to be the fastest-growing region in the global market, with a CAGR of 12.7%. This growth is attributed to a surge in the development of domestic ADCs, a rise in the prevalence of cancer, and growing ADC clinical trials in China.

Recent Developments

In May 2025, Astellas Pharma Inc. and Evopoint Biosciences entered into a licensing agreement for XNW27011. Under this agreement, Astellas is licensed to develop and commercialize XNW27011, a clinical-stage ADC targeting CLDN18.2.

Inquiry Before Buying @ https://straitsresearch.com/buy-now/antibody-drug-conjugates-market

List of Related Reports:

Antibody Contract Manufacturing Market Size: https://straitsresearch.com/report/antibody-contract-manufacturing-market

Antibody Production Market Size: https://straitsresearch.com/report/antibody-production-market

Blood Cancer Diagnostics Market Size: https://straitsresearch.com/report/blood-cancer-diagnostics-market

Lung Cancer Genomic Testing Market Size: https://straitsresearch.com/report/lung-cancer-genomic-testing-market

Breast Cancer Drugs Market Size: https://straitsresearch.com/report/breast-cancer-drugs-market

Breast Cancer Liquid Biopsy Market Size: https://straitsresearch.com/report/breast-cancer-liquid-biopsy-market

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/

About Us:

StraitsResearch.com is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services, along with providing business insights & market research reports.

This release was published on openPR.